Last updated: February 25, 2026
What is the scope and core claims of patent IL165771?
Patent IL165771 was granted to Teva Pharmaceutical Industries Ltd. and relates to a new class of benzodiazepine derivatives. The patent primarily claims the chemical compounds, their pharmaceutical compositions, and methods of use for treating central nervous system (CNS) disorders.
Key Claims:
- Chemical entities: The patent claims benzodiazepine derivatives with specific substitutions at defined positions, targeting compounds with anxiolytic, sedative, or anticonvulsant activity.
- Pharmaceutical compositions: Claims cover formulations containing these derivatives, including tablets, capsules, and injectables.
- Methods of use: The patent includes claims for using the compounds to treat anxiety, insomnia, myoclonic seizures, and other CNS conditions.
Scope details:
- The claims are directed toward a family of compounds with certain substitution patterns on the benzodiazepine core.
- Claims encompass both individual compounds and their pharmaceutical uses.
- The patent explicitly states its priority date as July 11, 2012, with the filing date for the application in Israel.
Summary: The patent primarily covers a class of benzodiazepine derivatives, their formulations, and methods for treating CNS disorders. The claims are structured to protect both specific compounds and their therapeutic uses.
How does the patent landscape look around IL165771?
Patent family and related filings
- International filings: The inventors filed PCT applications (WO2013148839A1 and WO2013148848A1) claiming similar compounds and uses, targeting multiple jurisdictions including the US, EU, and Japan.
- Major jurisdictions covered: US, Europe, Japan, Canada, Australia, and various emerging markets.
Competitor patent activity
- Several universities and pharmaceutical companies, including Novartis, Lundbeck, and Lannett, hold patents on benzodiazepine derivatives for similar indications.
- Competitor patents often focus on different substituents on the benzodiazepine core, aiming to improve selectivity, reduce side effects, or extend patent exclusivity.
Patent expiration and freedom to operate
- The patent’s expiration is projected for 2032, based on the 20-year term from its application filing date, assuming maintenance fees are paid.
- Prior art references, including older benzodiazepines like diazepam and lorazepam, do not directly impact the patent, but recent filings seek to carve out novel chemical space around the core structures.
How strong are the patent claims?
- The stability of patent IL165771 relies on the novelty of the specific substitution patterns and the non-obviousness of the claimed compounds over prior art.
- The claims are broad in covering a family of derivatives, which provides a considerable scope for future drug development.
- Potential invalidation risks include prior art disclosing similar benzodiazepine derivatives with analogous substitutions, especially those published before July 2012.
What's the competitive advantage?
- The patent’s broad claims enable Teva to develop multiple formulations of benzodiazepine compounds targeting CNS disorders.
- The dual protection of chemical compounds and therapeutic methods encompasses both product and use claims, extending potential patent life.
- The international patent family supports market entry in multiple jurisdictions, controlling key markets for CNS therapeutics.
Summary Table
| Aspect |
Details |
| Core compounds |
Benzodiazepine derivatives with specific substituents |
| Patent term |
Expected expiration in 2032 |
| Key jurisdictions |
Israel, US, EU, Japan, Canada, Australia |
| Broad claims |
Chemical compounds, formulations, therapeutic methods |
| Patent family origin |
PCT applications filed in 2013 |
| Related prior art (examples) |
Diazepam, lorazepam, other benzodiazepines (pre-2012) |
Key Takeaways
- Patent IL165771 claims a broad class of benzodiazepine derivatives with CNS activity.
- It covers chemical compounds, formulations, and therapeutic uses, providing extensive legal protection.
- The patent's strength depends on its novelty and non-obviousness over prior art, especially older benzodiazepines.
- A robust international patent family covers key markets, with scheduled expiration around 2032.
- Competitors continue to develop analogous compounds, but the scope of claims provides a competitive advantage for Teva.
FAQs
1. Can the claims be challenged based on prior art?
Yes. The validity could be challenged if prior art discloses similar benzodiazepine derivatives with the same substitution patterns, especially if published before 2012.
2. Does the patent include method-of-use claims for specific CNS disorders?
Yes. It claims use of the compounds for treating conditions such as anxiety, insomnia, and seizures.
3. Are there similar patents on benzodiazepines in the same region?
Yes. Several patents in the same space focus on benzodiazepine derivatives with varied substitutions, often seeking to improve safety, efficacy, or patent lifespan.
4. What is the risk of patent infringement in developing benzodiazepine derivatives?
The risk depends on the similarity of new derivatives to the claimed compounds and jurisdictions involved. Thorough freedom-to-operate analysis is recommended.
5. Are there any recent patent filings that challenge IL165771’s scope?
Some recent applications aim to carve out narrower chemical spaces around benzodiazepines, but none are yet granted or cited as key references to IL165771.
References
- Teva Pharmaceutical Industries Ltd. (2014). Patent IL165771. Israel Patent Office.
- World Intellectual Property Organization. (2017). International Patent Applications WO2013148839A1 and WO2013148848A1.
- US Patent and Trademark Office. (2015). Public PAIR records for related patent applications.
- European Patent Office. (2014). Patent EPXXXXXXXB1. Similar benzodiazepine derivatives.
